Published in Hematology Week, September 11th, 2006
"This prompted the investigation into whether blocking the erbB2 receptor alters differentiation of the airway epithelium," wrote investigators in the United States.
According to P.D. Vermeer and colleagues at the University of Iowa, "To test this hypothesis, we treated an in vitro model of well-differentiated human airway epithelia with trastuzumab or heregulin-alpha, an erbB ligand.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.